Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,501–2,600 of 3,704
Obesity Hypoventilation Syndrome
Lastra, A. C., Stewart, N. H., & Mokhlesi, B. (2024) · Respiratory medicine · doi:10.1007/978-3-031-52696-1_7 · Cited by 1
Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic
Qian, F., & Hu, F. B. (2024) · JAMA · doi:10.1001/jama.2024.7928 · Cited by 1
O USO DE TIRZEPATIDA NO COMBATE A OBESIDADE: UMA ANÁLISE DOS BENEFÍCIOS E EFEITOS ADVERSOS
dos Ramos, V. C. G., & de Oliveira, J. G. (2024) · Revista interdisciplinar em saúde · doi:10.35621/23587490.v11.n1.p500-515 · Cited by 1
Rethinking Behavioral Interventions for Adolescent Obesity
Carroll, A. E. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.1710 · Cited by 1
Consideration of Use of Semaglutide and Tirzepatide Prior to Pregnancy
Goldberg, A. S. (2024) · Canadian Women s Health Today · doi:10.58931/cwht.2024.1210 · Cited by 1
Thirzepatide. A novelty in the treatment of obesity - literature review
Wiśniewska, K., Gmitrzuk, J., Malinka, Z., Jachymek, A., Opatowska, M., Jakubiec, J., Kucharski, T., & Piotrowska, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.52005 · Cited by 1
Banack, H. R., Platt, R. W., & Matthay, E. C. (2024) · Current Epidemiology Reports · doi:10.1007/s40471-024-00353-3 · Cited by 1
Super response to liraglutide in people with obesity: A case report and literature review
Medina, S. G., Campayo, E. S., Guadalix, S., & Escalada, J. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.05.014 · Cited by 2
Zurita-Campos, J., Sánchez-López, I., & Lara, F. V.-O. D. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.08.002 · Cited by 1
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
Prescripción dietética en la hipertensión arterial
Vay‐Demouy, J., Fenech, G., Kantor, B., Cinaud, A., & Blacher, J. (2024) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(24)49670-0 · Cited by 2
Metabolische unerwünschte Arzneimittelwirkungen von Psychopharmaka
Gahr, M. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2405-5087 · Cited by 2
Cui, B., He, J., & Yao, H. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.10.014 · Cited by 3
Varughese, M. S., & Nayak, A. (2024) · Eye · doi:10.1038/s41433-024-03426-1 · Cited by 1
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Grave, R. D. (2024) · IJEDO · doi:10.32044/ijedo.2024.02 · Cited by 1
New class of drugs for the treatment of diabetes mellitus
Islamova, A. I., Sabirova, A. R., Batyrshina, E. R., Muzafarova, G. N., Khabibullina, L. H., Kiraeva, A. E., Pyatyshina, A. V., Arslanova, E., Vinnikova, A. A., Pisarev, A. A., et al. (2024) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2024-102-7-499-509 · Cited by 1
Medications for obesity as preventatives: a public and patient safety issue
Flint, S. W., Brown, A. C., Vázquez‐Velázquez, V., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00319-x · Cited by 1
Healy, W. J., Kundel, V., Taub, P. R., Cho, Y., Healy, S. J., & Kwon, Y. (2024) · SLEEP Advances · doi:10.1093/sleepadvances/zpae094 · Cited by 1
GLP-1 Agonists for Weight Loss and Beyond
Quinter, C., Motilall, H., & Maberry, K. (2024) · Transformative Medicine · doi:10.54299/tmed/curq6915
中田, 亮., 千原, 直., 櫻澤, 信., 谷合, 信., & 吉田, 寛. (2024) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.20.282 · Cited by 1
Ojaimi, R. E., Cheisson, G., Cosson, E., Ichaï, C., Jacqueminet, S., Catargi, B., Ouattara, A., Tauveron, I., Valensi, P. E., & Benhamou, D. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101468 · Cited by 1
Kim, K., Jung, J., Um, Y. H., Ahn, Y., Ko, S., Han, K., & Yun, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01559-7 · Cited by 2
Wadhawan, R. (2024) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_17_24 · Cited by 1
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Thomas, T. S., & Srinivasa, S. (2024) · PubMed Central · Cited by 7
Food Bioactives in the Prevention and Clinical Management of Obesity
Laya, A., Carvalho, E., Fernandes, I., Oliveira, J., Siewe, F. B., Wangso, H., & Djakba, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-9723-3_13 · Cited by 1
Liu, Y., Yuan, H., Hu, J., Xu, X., Yin, S., Hu, Y., & Liu, F. (2025) · Journal of Obesity · doi:10.1155/jobe/7821115 · Cited by 2
Type 2 Diabetes and Sarcopenia
Sathyakumar, S. (2025) · Apollo Medicine · doi:10.1177/09760016251326660 · Cited by 4
Interventions to prevent or treat obesity in adult Indigenous Australians: A systematic review
Lan, N. S. R., Ford, J., Gregory, L., Jones, G., Dwivedi, G., & Yeap, B. B. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.04.003 · Cited by 1
Gartner, H. T., Simmons, R. E., Wan, H. Z., Sollee, D. R., & Sheikh, S. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251334642 · Cited by 1
A Probable Case of Tirzepatide-Induced Acute Pancreatitis
Sumaruth, Y. R. K., Gopal, R., Chater, F., Dhawan, S., & Wild, T. (2025) · Cureus · doi:10.7759/cureus.85291 · Cited by 7
Jeon, J. H., & Kang, D. W. (2025) · Tetrahedron Letters · doi:10.1016/j.tetlet.2025.155730 · Cited by 1
Tirzepatide: a dual approach to combat obesity and obstructive sleep apnea
Naseem, S., Afreen, S., Fareha, S., Pushpa, C., & Reja, M. H. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20252496 · Cited by 1
Alolayan, S. A., & Alhowail, A. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1638527 · Cited by 3
US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Karthikeyan, H., Fan, W., & Wong, N. D. (2025) · Diabetes and Vascular Disease Research · doi:10.1177/14791641251376551 · Cited by 1
Carr, L. T. B., Ard, J. D., Shanks, C. B., Forman, E. M., Goldstein, S. P., Haire-Joshu, D. L., Jastreboff, A. M., Johnson, S. M., Kandula, N. R., Katzmarzyk, P. T., et al. (2025) · Obesity · doi:10.1002/oby.70035 · Cited by 3
Self-citationFrom liver fat to full-blown metabolic disorder: the kidney as target organ
Petroni, M. L., & Marchesini, G. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.17 · Cited by 1
Next Step in Incretin-Based Therapy: From Single to Dual Agonism
Pramanik, S., & Ray, S. (2022) · EMJ Diabetes · doi:10.33590/emjdiabet/22-00140 · Cited by 2
Insulin sensitive human adipocytes for in vitro studies
Straub, L. G., & Scherer, P. E. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00727-x · Cited by 1
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Winkler, G., Kis, J. T., & Schandl, L. (2022) · Lege Artis Medicinae · doi:10.33616/lam.32.019 · Cited by 4
Non-pharmacologic treatment for obesity
Koo, B. K. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.7.400 · Cited by 1
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 2
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Klein, L. W. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.040 · Cited by 1
Les traitements médicamenteux dans l’obésité
Carette, C., Rives‐Lange, C., & Czernichow, S. (2023) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2022.12.002 · Cited by 3
Tirzepatide Reduced Significantly the Body Weight in Obese Patients
Gerő, L. (2022) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2022.16.555930 · Cited by 1
Ketogenic diets for obesity‐hypoventilation syndrome? Interesting physiology but a long way to go
Cayanan, E. A., & Grunstein, R. R. (2023) · Respirology · doi:10.1111/resp.14540 · Cited by 1
A duális antidiabetikus hatású kombináció, a tirzepatid
Gerő, L. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.4
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_25 · Cited by 3
Obesity, Metabolic Syndrome, and Sleep Disorders
Duan, D., & Jun, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_53 · Cited by 4
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Primary care physicians’ perceptions of the effects of being overweight on all-cause mortalityPreprint
Mathur, M. B., & Mathur, V. S. (2022) · doi:10.31219/osf.io/q8bvn · Cited by 1
Horn, D. B. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.03.011 · Cited by 1
Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment providerPreprint
Ard, J. D., Hong, Y., Foster, G. D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3959336/v1 · Cited by 1
Cancer-Associated Hypercalcemia Signals Through the Hindbrain to cause AnorexiaPreprint
Grinman, D. Y., Takyar, F. M., Dann, P. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.19.585694 · Cited by 1
Zinn, J., & Poretsky, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4022269/v1 · Cited by 1
Samuels, J. M., Niswender, K. D., Roumie, C. L., et al. (2024) · medRxiv · doi:10.1101/2024.04.21.24306138 · Cited by 1
Bueter, M., Peterli, R., & Salminen, P. T. P. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07494-w · Cited by 1
Endoscopic Sleeve Gastroplasty as a therapeutic option for class III obesityPreprint
Bove, V., Pontecorvi, V., Gualtieri, L., Matteo, M. V., Siena, M. D., Carlino, G., Giannetti, G., Iaconelli, A., Ficuccilli, L., Ciasca, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5311171/v1 · Cited by 1
Deep phenotyping obesity using EHR data: Promise, Challenges, and Future DirectionsPreprint
Ruan, X., Lu, S., Wang, L., Wen, A., Murali, S. B., & Liu, H. (2024) · medRxiv · doi:10.1101/2024.12.06.24318608 · Cited by 1
Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT
Karakasis, P., Fragakis, N., Ruža, I., Stachteas, P., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2477429 · Cited by 2
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672374 · Cited by 1
Kumar, A., Scroggie, S., Sarkar, T. D., Hepokoski, M., & Malhotra, A. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561067 · Cited by 1
Hait, A., & CHOUDHARY, A. K. (2025) · Research Square · doi:10.21203/rs.3.rs-8265802/v1 · Cited by 1
Moll, H., Puhan, M. A., Gerber, P. A., Beuschlein, F., Frenes, K., Spanu, A., Walter, J. E., & Yebyo, H. G. (2025) · medRxiv · doi:10.64898/2025.12.15.25342259 · Cited by 2
Incretin-based therapies for obesity and disordered eating: optimising care in general practice
Atlantis, E. E., Wu, R., & Dixon, J. (2026) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003622 · Cited by 2
Governor, S., Essien, E., Agyekum, A. K., Ahsan, A., Wiesel, S., Khurana, D., El‐Kersh, K., Altaee, O., Otchere, P., & Dávila‐Román, V. G. (2026) · medRxiv · doi:10.64898/2026.01.20.26344489 · Cited by 1
Domagała, K., Abramowicz, A. D., Rumin, M., Tatarata, O., Osuch, M., Osuch, M., Kiełboń, A., Jaciubek, M., Luty, C., & Reklewska, Z. O. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5125
Prescription diététique dans l'hypertension artérielle
Kaboré, J., Lelong, H., Agnoletti, D., Safar, M. E., & Blacher, J. (2014) · Time to knit · doi:10.1016/s1877-7848(24)49787-6
看護で防ぐVAP対策のケアの実際と工夫 (特集 押さえておきたい誤嚥性肺炎とVAPの最新ケア)
石鉢, 一. (2010) · 臨床看護
Kober, F., Soghomonian, A., & Dutour, A. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28339
Apport de la génétique dans l’obésité de l’enfant
Faccioli, N., Courbage, S., & Dubern, B. (2022) · Perfectionnement en Pédiatrie · doi:10.1016/j.perped.2022.07.029 · Cited by 1
Who knew? PPARs may act in the brain too
Seeley, R. J., & Rhodes, C. J. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00625-6
Editorial: Hungry for more: What's new in appetite regulation
Murphy, K. G., & Bewick, G. A. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100417
Reframing the need for exercise therapy in the clinical management of people living with obesity
Grannell, A. (2022) · Clinical Obesity · doi:10.1111/cob.12554 · Cited by 1
Twinkretin bremst Nephropathieprogression
Fritschka, E. (2022) · Info Diabetologie · doi:10.1007/s15034-022-3860-z
Extent of Role: Anti-Diabetic Medications
Hong, J. H. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.3.153
New research on treating obesity through medical and behavioural intervention
Mendes, A. (2022) · Journal of Prescribing Practice · doi:10.12968/jprp.2022.4.10.424
Müller, T. D. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1904-5552
Neues Antidiabetikum setzt Maßstab als Adipositasmittel
Schumacher, B., & Patzer, K.-H. (2022) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-022-2014-5
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1886-3659
Inkretine: Hoffnungsschimmer für Jugendliche mit Adipositas und/oder Typ-2-Diabetes
(2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1925-0005
Update on technologies, medicines and treatments
O’Neill, S. (2022) · Diabetic Medicine · doi:10.1111/dme.14985
Adipositas: Tirzepatid sicher und wirksam?
(2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1916-2653
Diagnose und Therapie der idiopathischen intrakraniellen Hypertension
Higgen, F. L. (2022) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-022-3047-0
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115349
Endocrinologie, un nouveau traitement de l’obésité chronique
Manus, J.-M. (2022) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(22)00367-7
Adipositas: Tirzepatid sicher und wirksam?
Simon, A. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1958-1667
Neues Antidiabetikum setzt Maßstab als Adipositasmittel
Schumacher, B. (2022) · CardioVasc · doi:10.1007/s15027-022-2932-2
Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution
Oveyssi, J., & Huang, E. (2022) · Transplantation · doi:10.1097/tp.0000000000004374
Efficience et précision du contrôle glycémique dans le diabète : symphonie inachevée ?
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.005
Overview of the hybrid 82nd Scientific Sessions of the American Diabetes Association
Day, C. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.391
Day, C. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.392
Schlienger, J.-L., & Monnier, L. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.006 · Cited by 5
Tirzepatide: Revolutionary Drug in Management of “Diabesity”
Chouhan, V., Spal, S., & Kumar, R. (2022) · International Journal of Medical and Dental Sciences · doi:10.18311/ijmds/2022/636 · Cited by 1
Effect of tirzepatide on prediabetics and blood pressure with implications for future research
Seetharaman, R. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2022-0305
Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight
Sankaran, L., & Curtis, L. R. (2023) · Practical Diabetes · doi:10.1002/pdi.2432
GLP -1 agonists for weight loss: What you need to know
Goldberg, J. F. (2023) · Current Psychiatry · doi:10.12788/cp.0318
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230320 · Cited by 2
Avenir de la chirurgie bariatrique au-delà de la surcharge pondérale : la chirurgie métabolique
Caiazzo, R. J., Marciniak, C., Rémond, A., Baud, G., & Pattou, F. N. (2023) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2023.01.002 · Cited by 1
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.